Trial Profile
A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With WHO or ISN Class III or IV Nephritis Due to Systemic Lupus Erythematosus
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 01 Jan 2024
Price :
$35
*
At a glance
- Drugs Ocrelizumab (Primary) ; Corticosteroids; Corticosteroids; Cyclophosphamide; Mycophenolate mofetil
- Indications Lupus nephritis
- Focus Registrational; Therapeutic Use
- Acronyms BELONG
- Sponsors Genentech
- 15 Nov 2023 Initial post hoc analysis of patients in the control arms of the LUNAR and BELONG trial presented at the ACR Convergence 2023
- 01 Mar 2023 Results comparing differences between B-cell depletion in lupus nephritis patient populations who received rituximab (LUNAR), ocrelizumab (BELONG), or obinutuzumab (NOBILITY), published in the Clinical Immunology
- 20 Dec 2021 This trial has been completed in Hungary, according to European Clinical Trials Database record.